July 11, 2019
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190711005777/en/
Ms. Shaw is a renowned leader with deep experience providing commercial, financial, strategic, medical and operations leadership across the biopharmaceutical industry. Ms. Shaw currently serves as Senior Vice President of
Prior to joining Lilly, Ms. Shaw most recently served as U.S. Country Head and President of
“We conducted an extensive search for a new leader at Kite and we believe that Christi’s unique set of skills will allow us to continue to build on our leadership position in cell therapy,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “Christi’s vast experience across complex therapeutic areas, and particularly in oncology, will serve Kite very well. She is clearly a leader who will bring teams and individuals together and I am confident she will build upon the entrepreneurial spirit at Kite as we seek to help more people with cancer around the world.”
“Kite’s vision of transformational drug development – and of curing cancer – is one that I am extremely passionate about,” said Ms. Shaw. “I look forward to working with the many talented individuals in this organization, as we change the way cancer is treated and bring forward important, life-saving therapies.”
About Kite
Kite, a
About
For more information on Kite, please visit the company’s website at www.kitepharma.com. Learn more about Gilead at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190711005777/en/
Source:
Sung Lee, Investors
(650) 524-7792
Shant Salakian, Media
(424) 384-1841